Survival outcomes including median PFS and OS for early and late transfusions, as well as NRM and LRM in the different populations
| A . | Median PFS (months) . | Median OS (months) . | ||||
|---|---|---|---|---|---|---|
| Transfused . | Not transfused . | P value . | Transfused . | Not transfused . | P value . | |
| Early RBC (<1 mo) | 3.1 | 6.0 | .0042 | 9.0 | 21.1 | <.0001 |
| Early platelets (<1 mo) | 3.1 | 5.8 | .0054 | 7.8 | 21.1 | <.0001 |
| Late RBC (≥ 1 mo) | 8.8 | 8.5 | .7199 | 20.6 | 24.1 | .0971 |
| Late platelets (≥ 1 mo) | 5.6 | 12.0 | .0072 | 13.8 | Not reached | <.0001 |
| A . | Median PFS (months) . | Median OS (months) . | ||||
|---|---|---|---|---|---|---|
| Transfused . | Not transfused . | P value . | Transfused . | Not transfused . | P value . | |
| Early RBC (<1 mo) | 3.1 | 6.0 | .0042 | 9.0 | 21.1 | <.0001 |
| Early platelets (<1 mo) | 3.1 | 5.8 | .0054 | 7.8 | 21.1 | <.0001 |
| Late RBC (≥ 1 mo) | 8.8 | 8.5 | .7199 | 20.6 | 24.1 | .0971 |
| Late platelets (≥ 1 mo) | 5.6 | 12.0 | .0072 | 13.8 | Not reached | <.0001 |
| B . | NRM (%) . | LRM (%) . | ||||
|---|---|---|---|---|---|---|
| Transfused . | Not transfused . | P value . | Transfused . | Not transfused . | P value . | |
| Early RBC (< 1 mo) | 12.3 | 8.2 | .095 | 44.8 | 35.3 | .014 |
| Early platelets (< 1 mo) | 14.3 | 7.6 | .008 | 46.0 | 36.0 | .012 |
| Late RBC (≥ 1 mo) | 14.0 | 6.9 | .010 | 34.3 | 32.5 | .697 |
| Late platelets (≥ 1 mo) | 14.9 | 6.2 | .001 | 38.7 | 30.4 | .054 |
| B . | NRM (%) . | LRM (%) . | ||||
|---|---|---|---|---|---|---|
| Transfused . | Not transfused . | P value . | Transfused . | Not transfused . | P value . | |
| Early RBC (< 1 mo) | 12.3 | 8.2 | .095 | 44.8 | 35.3 | .014 |
| Early platelets (< 1 mo) | 14.3 | 7.6 | .008 | 46.0 | 36.0 | .012 |
| Late RBC (≥ 1 mo) | 14.0 | 6.9 | .010 | 34.3 | 32.5 | .697 |
| Late platelets (≥ 1 mo) | 14.9 | 6.2 | .001 | 38.7 | 30.4 | .054 |
LRM, lymphoma-related mortality.
Values in bold signify statistical significance (p<0.05).